Brief: Firebrick Pharma Announces License Agreement For Singapore, Malaysia, Brunei, Mauritius
26/08/2025 02:16
Aug 26 (Reuters) - Firebrick Pharma Ltd FRE.AX: LICENSE AGREEMENT FOR SINGAPORE, MALAYSIA, BRUNEI, MAURITIUS NEW AGREEMENT EXPECTED TO SIGNIFICANTLY REDUCE FIREBRICK'S MARKETING EXPENSES IN FY26 INNORINI APPOINTED EXCLUSIVE LICENSEE FOR NASODINE PRODUCTS IN SINGAPORE, MALAYSIA, BRUNEI AND MAURITIUS Further company coverage: FRE.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Firebrick Pharma
See all newsAustralia's Firebrick Pharma jumps on plan to launch Nasodine products in US retail market
Brief: Firebrick Pharma Receives A$293,000 Research And Development Tax Incentive
Brief: Firebrick Pharma Says Nasodine Composition Patent Granted In New Zealand
Brief: Firebrick Pharma Says Nasodine Patent Accepted In Canada
Brief: Firebrick Pharma Secures A$1.5 Million Via Placement